Morgan Stanley Maintains Equal-Weight on Cytek Biosciences, Lowers Price Target to $5.5

Morgan Stanley analyst Tejas Savant maintains Cytek Biosciences (NASDAQ:CTKB) with a Equal-Weight and lowers the price target from $6 to $5.5.